ViCardia Therapeutics Inc.
San Francisco, USA
|
Description:
ViCardia Therapeutics, Inc., is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapies for treating heart failure (HF) involving mitochondrial dysfunction. The company’s lead compound, GP531, is a potent, orally active, second-generation adenosine regulating agent, that targets mitochondrial dysfunction, reversing the decline in the production of cellular energy in the form of adenosine triphosphate (ATP), and improving cardiac function....
ViCardia Therapeutics, Inc., is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapies for treating heart failure (HF) involving mitochondrial dysfunction. The company’s lead compound, GP531, is a potent, orally active, second-generation adenosine regulating agent, that targets mitochondrial dysfunction, reversing the decline in the production of cellular energy in the form of adenosine triphosphate (ATP), and improving cardiac function....